Nasdaq Congratulates Signifier Medical Technologies for Treating 10,000 Patients With eXciteOSA, a Daytime Therapy for Sleep Apnea
Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announces that eXciteOSA, the only FDA-authorized daytime therapy for sleep-disordered breathing, has treated over 10,000 patients since the commercial launch in 2021. Nasdaq recognized this milestone by congratulating Signifier Medical on the Nasdaq Tower in the heart of Times Square, New York.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230329005432/en/
(Photo: Business Wire)
Akhil Tripathi, Signifier’s co-founder and CEO said, “This is a proud moment knowing that our therapy has made a positive impact on the lives of so many patients. It’s been a great team effort among our employees, clinicians, distributors, and most of all, our patients.” Signifier Medical is simplifying the complex standard of care for obstructive sleep apnea with eXciteOSA by tackling a root cause -- empowering patients to restore their nighttime breathing naturally – with a novel 20-minute daytime therapy.
Past studies have shown that eXciteOSA is associated with reductions in both objectively measured and bed-partner-reported snoring, along with significant improvements in disease severity, measured by the Epworth Sleepiness Scale, and Pittsburgh Sleep Quality Index.1-3 Clinical trial participants experienced a significant reduction in their AHI overall.3
“eXciteOSA is a new and novel daytime treatment for sleep apnea. Burden of use is as low as 20 minutes. Evidence is mounting about the positive effects of eXciteOSA in improving disease severity and daytime sleepiness. Patients now have an alternative approach that is easy to use and well accepted,” said Dr. Naresh M. Punjabi, Ph.D. – Chief, Division of Pulmonary, Critical Care, and Sleep Medicine at the University of Miami.
eXciteOSA is a smart wireless device used for 20 minutes per day paired with an intuitive app and a dedicated Sleep Advocate for one-on-one coaching and support. Joel Hanlon, Manager of Patient Experience, said, “We’re thrilled with how well patients are responding to therapy, and we’re here to support them every step of the way throughout their therapy journey.”
The current standard of care for treating OSA, positive airway pressure (PAP), has long been plagued with low adherence and low patient satisfaction. Based on a recent study, eXciteOSA therapy demonstrates real-world adherence of more than 80%, which is exceptional in this space.
Effective treatment of OSA, which leads to better sleep, unlocks the potential for each of us to do more of what we love in life. We have a good reminder of that this month -- March – which is Sleep Awareness Month. It’s a good time to learn about sleep health and seek a diagnosis and treatment for sleep-related conditions. Signifier Medical would like to be a part of that -- transforming the standard of care for sleep apnea to help the millions of those suffering from the condition.
About Signifier Medical Technologies
Signifier is a pioneer in addressing the root causes of sleep-disordered breathing. The Company is focused on the development and commercialization of innovative and non-invasive solutions to help people breathe normally and naturally all night – without needing to use a wearable medical device or a surgical implant. Founded in 2015, Signifier is at the forefront of sleep therapy, with a mission to develop therapies to improve population health, increase the quality of patient’s healthcare experience, and generate healthcare savings. Signifier has offices in London (UK) and Needham (Massachusetts, USA).
About eXciteOSA
eXciteOSA is a revolutionary daytime therapy for sleep-disordered breathing. Clinically proven to target a common root cause of OSA, eXciteOSA uses neuromuscular electrical stimulation (NMES) to “exercise” the upper airway muscles, working the intrinsic and extrinsic tongue muscles to improve endurance and prevent airway collapse during sleep. Unlike other devices which are used while patients sleep, eXciteOSA is the first commercially available device used while awake.
Signifier is dedicated to engaging with the sleep research community to produce high-quality evidence from rigorous clinical trials. Randomized trials are in progress to understand the potential placebo effect (NCT04974515), the impact of therapy relative to usual care without treatment (NCT05183009; NCT05252156), and the impact of therapy amongst those with moderate OSA (NCT05252156).
For more information, please visit www.signifiermedical.com or www.exciteosa.com.
References
- Baptista PM, Martinez Ruiz de Apodaca P, Carrasco M, Fernandez S, Wong PY, Zhang H, Hassaan A, Kotecha B. Daytime neuromuscular electrical therapy of tongue muscles in improving snoring in individuals with primary snoring and mild obstructive sleep apnea. Journal of Clinical Medicine 2021;10(9):1-11.
- Wessolleck E, Bernd E, Dockter S, Lang S, Sama A, Stuck BA. Intraoral electrical muscle stimulation in the treatment of snoring. Somnologie 2018;22(2):47-52.
- Nokes B, Baptista PM, de Apodaca PMR, Carrasco-Llatas M, Fernandez S, Kotecha B, Wong PY, Zhang H, Hassaan A, Malhotra A. Transoral awake state neuromuscular electrical stimulation therapy for mild obstructive sleep apnea. Sleep Breath 2022;
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230329005432/en/
Contact information
Media:
Jay Cranston
Signifier Medical Technologies Inc
jay.c@signifiermedical.com
Investors and Partners:
Ekin Sezgen
Signifier Medical Technologies Inc
ekin.s@signifiermedical.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galtronics Improves Attendee Experience at NFL Stadiums and MLB Ballparks Nationwide9.6.2023 12:00:00 EEST | Press release
Galtronics, the company that combines collaboration with technology innovation to solve the world’s most complex wireless connectivity challenges, today announced distributed antenna system (DAS) upgrades across four major stadiums. Galtronics’ antennas will be deployed at Arrowhead Stadium, home of the defending Super Bowl Champion Kansas City Chiefs; Ford Field, home of the Detroit Lions; Bank of America Stadium, home of the Carolina Panthers; and T-Mobile Park, home of the Seattle Mariners. The recent upgrades will provide increased sectorization to drive higher levels of capacity and data speeds, allowing fans to stream other sporting events, keep up with fantasy team stats or share live event interaction over social platforms. In total, Galtronics is providing 705 antennas across the three stadiums and ballpark. The C-Band antenna upgrades range from HyperFlat (Ceiling mount Omni DAS Antenna), Small Panel antennas and a combination of 30x30 and 30x60 Stadium Panel Antennas. They w
Superior Graphite to Build 24.000 Ton Per Annum Active Anode Material Capacity at 1/3 the CapEx Cost9.6.2023 11:38:00 EEST | Press release
Superior Graphite, a leading producer of graphite, plans to construct a USD180 million anode materials facility to meet the accelerating demand for EV’s and energy storage in the North American and European markets. The company's state-of-the-art Anode Active Material (AAM) enables and accelerates the energy transition. The main facility will be in Hopkinsville, Kentucky, with additional capacity in Sundsvall, Sweden. Superior Graphite's innovative production technology and established operations at these locations result in a continuous production process, significantly reducing capital requirements and operational costs. "Our technology and product brands are trusted by high-volume customers worldwide. Our unique technology uses approximately 70% less electricity, labor, and space compared to traditional production processes. The carbon footprint is reduced by nearly 85%, and the cost savings for EV companies are substantial," says Ed Carney, CEO of Superior Graphite. Meeting the IRA
Mega Refining and Petrochemical Plant Selects Hytera as Provider of Professional Communications System9.6.2023 11:08:00 EEST | Press release
Hytera, a global leading provider of professional communication technologies and solutions, has been selected as the supplier of professional communications solution for the Yulong Island Refining and Petrochemical Integration Project in Shandong Province, China. Hytera won this public tender with its advanced professional digital trunking (PDT) infrastructure, control and dispatch system , network management system (NMS), digital voice recording system (DVRS), and intrinsically safe (IS) PDT two-way radios . This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230609005125/en/ PD790Ex Intrinsically Safe PDT Two-way Radio (Graphic: Business Wire) The Yulong project is the largest refining and petrochemical facility being constructed in China. With a projected overall production capacity of 40 million tons per year, this plant is a strategic venture aimed at driving economic growth, enhancing energy production capabilities, and pro
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress9.6.2023 10:01:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that both pivotal trials for exagamglogene autotemcel (exa-cel) in patients with transfusion-dependent beta thalassemia (TDT) or severe sickle cell disease (SCD) met primary and key secondary endpoints at pre-specified interim analyses. The results are being presented at the Annual European Hematology Association (EHA) Congress. “The updated results from both the TDT and SCD trials are remarkable and bring the promise of an autologous CRISPR/Cas9 gene-edited cell therapy one-step closer to patients who are waiting,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. “This analysis confirms the potential of exa-cel to render patients transfusion-independent or VOC-free, with significant improvement in their quality of life and physical performance,” said Franco Locatelli, M.D., Ph.D., Professor of
Capcom Turns 40 on June 119.6.2023 10:00:00 EEST | Press release
Capcom Co., Ltd. (TOKYO:9697) will celebrate its 40th anniversary on June 11, 2023, as the date marks forty years since the company’s founding on June 11, 1983. In recognition of this achievement, Capcom is conveying its gratitude to its global stakeholders for their ongoing support over the past 40 years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230609005095/en/ Capcom celebrates 40th anniversary with announcement in the Financial Times. (Graphic: Business Wire) To mark the 40th anniversary of its founding, Capcom is taking its slogan of “from Osaka, to the world,” and sending a message of gratitude to its supporters worldwide. This includes a full-page announcement of the 40-year milestone published in the June 9 edition of the Financial Times conveying the company’s appreciation to stakeholders around the globe for their support in helping Capcom deliver the fun and excitement of its highly creative, original conten
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom